SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics

SAB Biotherapeutics, Inc., (SABS): $3.06

0.18 (-5.56%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add SABS to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#93 of 393

in industry

SABS Price/Volume Stats

Current price $3.06 52-week high $9.72
Prev. close $3.24 52-week low $2.16
Day low $3.00 Volume 69,400
Day high $3.32 Avg. volume 31,532
50-day MA $2.97 Dividend yield N/A
200-day MA $3.53 Market Cap 28.24M

SABS Stock Price Chart Interactive Chart >


SAB Biotherapeutics, Inc., (SABS) Company Bio


SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.


SABS Latest News Stream


Event/Time News Detail
Loading, please wait...

SABS Latest Social Stream


Loading social stream, please wait...

View Full SABS Social Stream

SABS Price Returns

1-mo 7.37%
3-mo 15.04%
6-mo 12.50%
1-year -67.45%
3-year -96.91%
5-year N/A
YTD -55.49%
2023 16.55%
2022 -92.45%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!